| Budget Amount *help |
¥21,970,000 (Direct Cost: ¥16,900,000、Indirect Cost: ¥5,070,000)
Fiscal Year 2013: ¥7,150,000 (Direct Cost: ¥5,500,000、Indirect Cost: ¥1,650,000)
Fiscal Year 2012: ¥6,890,000 (Direct Cost: ¥5,300,000、Indirect Cost: ¥1,590,000)
Fiscal Year 2011: ¥7,930,000 (Direct Cost: ¥6,100,000、Indirect Cost: ¥1,830,000)
|
|---|
| Research Abstract |
We identified that senescent associated miRNA, SA-miRNA, miR-22 is down-regulated in various cancer cell lines including MCF-7, MDA-MB-231 and SiHa cells, suggesting that miR-22 should play important roles for cancer progression. Transfection of miR-22 strongly induces cellular senescence accompanied by enlarged morphology, senescent-associated b-Gal activity (SA-b-Gal) and senescent associated heterochromatin foci (SAHF) formation. By using 3-UTR luciferase assay and Western analysis, we identified CDK6, SP-1, SIRT1 and Histone H3.3 are targets of miR-22. Furthermore, synthetic miR-22 delivery significantly suppresses tumor growth and metastasis in vivo in a murine breast metastasis cancer model using MDA-MB-231 Luc cell lines. Our study provides the first evidence that the senescence-associated miRNA induces cellular senescence in human fibroblasts and cancer cells, and acts as tumor suppressor to play an important role in tumorigenesis.
|
